Quality-of-Life and Economic Outcomes of Assessing Fractional Flow Reserve With Computed Tomography Angiography PLATFORM by Hlatky, Mark A. et al.
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 2 1 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 9 . 0 5 1Quality-of-Life and Economic Outcomes
of Assessing Fractional Flow Reserve With
Computed Tomography Angiography
PLATFORMMark A. Hlatky, MD,* Bernard De Bruyne, MD, PHD,y Gianluca Pontone, MD, PHD,z Manesh R. Patel, MD,x
Bjarne L. Norgaard, MD,k Robert A. Byrne, MB BCH, PHD,{ Nick Curzen, BM (HONS), PHD,# Ian Purcell, MD,**
Matthias Gutberlet, MD,yy Gilles Rioufol, MD,zz Ulrich Hink, MD,xx Herwig Walter Schuchlenz, MD,kk
Gudrun Feuchtner, MD,{{ Martine Gilard, MD,## Daniele Andreini, MD,z Jesper M. Jensen, MD,k
Martin Hadamitzky, MD,{ Alan Wilk, BS,*** Furong Wang, MD,*** Campbell Rogers, MD,*** Pamela S. Douglas, MD,x
for the PLATFORM InvestigatorsABSTRACTFro
Sta
Ca
kDBACKGROUND Fractional ﬂow reserve estimated using computed tomography (FFRCT) might improve evaluation of
patients with chest pain.
OBJECTIVES The authors sought to determine the effect on cost and quality of life (QOL) of using FFRCT instead of
usual care to evaluate stable patients with symptoms suspicious for coronary disease.
METHODS Symptomatic patients without known coronary disease were enrolled into 2 strata based on whether
invasive or noninvasive diagnostic testing was planned. In each stratum, consecutive observational cohorts were
evaluated with either usual care or FFRCT. The number of diagnostic tests, invasive procedures, hospitalizations, and
medications during 90-day follow-up were multiplied by U.S. cost weights and summed to derive total medical costs.
Changes in QOL from baseline to 90 days were assessed using the Seattle Angina Questionnaire, the EuroQOL, and a
visual analog scale.
RESULTS In the 584 patients, 74% had atypical angina, and the pre-test probability of coronary disease was 49%. In the
planned invasive stratum,mean costswere 32% lower among the FFRCT patients than among the usual care patients ($7,343
vs. $10,734p<0.0001). In the noninvasive stratum,mean costswere not signiﬁcantly different between the FFRCT patients
and the usual care patients ($2,679 vs. $2,137; p¼ 0.26). In a sensitivity analysis, when the cost weight of FFRCT was set to
7 times that of computed tomography angiography, the FFRCT group still had lower costs than the usual care group in the
invasive testing stratum ($8,619 vs. $ 10,734; p < 0.0001), whereas in the noninvasive testing stratum, when the cost
weight of FFRCT was set to one-half that of computed tomography angiography, the FFRCT group had higher costs than the
usual care group ($2,766vs. $2,137; p¼0.02). EachQOL score improved in the overall studypopulation (p<0.0001). In the
noninvasive stratum, QOL scores improvedmore in FFRCT patients than in usual care patients: Seattle Angina Questionnaire
19.5 versus 11.4, p¼ 0.003; EuroQOL 0.08 versus 0.03, p¼ 0.002; and visual analog scale 4.1 versus 2.3, p¼ 0.82. In the
invasive cohort, the improvements in QOL were similar in the FFRCT and usual care patients.
CONCLUSIONS An evaluation strategy based on FFRCT was associated with less resource use and lower costs within
90 days than evaluation with invasive coronary angiography. Evaluation with FFRCT was associated with greater
improvement in quality of life than evaluation with usual noninvasive testing. (Prospective Longitudinal Trial of
FFRCT: Outcomes and Resource Impacts [PLATFORM]; NCT01943903) (J Am Coll Cardiol 2015;66:2315–23)
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ABBR EV I A T I ON S
AND ACRONYMS
CAD = coronary artery disease
CTA = computed tomography
angiography
EQ-5D = EuroQOL, 5-item
version
FFR = fractional ﬂow reserve
FFRCT = fractional ﬂow reserve
estimated with computed
tomography
PCI = percutaneous coronary
intervention
QOL = quality of life
SAQ = Seattle Angina
Questionnaire, 7-item version
VAS = visual analog scale
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2316E valuation of patients with the newonset of symptoms suggestive of cor-onary artery disease (CAD) is difﬁcult
due to the many testing options. Noninvasive
stress testing, often combined with myocar-
dial perfusion imaging or echocardiography,
is recommended for stable patients who
have an intermediate pre-test probability of
CAD (1). Invasive coronary angiography is
recommended as an initial test for patients
with a high pre-test probability of CAD (1),
but invasive angiography does not assess
the functional signiﬁcance of visualized le-
sions, and it is more costly and carries greater
risk than noninvasive testing. Noninvasive
coronary computed tomography angiography
(CTA) is very sensitive in detecting obstruc-tive CAD, but is limited in its positive predictive
value. CTA also does not assess the functional signif-
icance of visualized lesions, and often leads to further
evaluation with either stress testing or invasive angi-
ography, or both (2–4).SEE PAGE 2324Fractional ﬂow reserve (FFR) assesses the func-
tional signiﬁcance of individual coronary lesions, and
has been used to guide use of percutaneous coronary
intervention (PCI). FFR measured during invasive
coronary angiography identiﬁed patients for whom
performing PCI was cost-effective compared with
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tomography data (FFRCT), based on computational
ﬂuid dynamics (6). FFRCT was recently cleared for
clinical use by the U.S. Food and Drug Administration,
and in 2011 received a CE mark in Europe. The clinical
effectiveness of a strategy of using FFRCT to guide
management, compared with conventional testing,
has been recently demonstrated in PLATFORM (Pro-
spective Longitudinal Trial of FFRCT: Outcomes and
Resource Impacts) (7). The purpose of this studywas to
assess the quality of life and economic outcomes of
evaluation strategies that use FFRCT, based on data
collected prospectively from the PLATFORM study.
METHODS
The design (8) and main results (7) of the PLATFORM
study have been previously described. Brieﬂy,
between September 10, 2013, and November 26,
2014, PLATFORM enrolled 2 consecutive cohorts of
patients with suspected CAD in 11 European centers.
Patients were eligible for enrollment if they were
symptomatic, had an intermediate likelihood of
CAD (between 20% and 80%), did not have an
established diagnosis of CAD, and were referred for
clinically indicated testing to evaluate CAD. Patients
referred for noninvasive testing were enrolled in
a separate stratum than patients referred for
invasive testing. The choice to refer the patient for
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TABLE 1 Baseline Clinical Characteristics by Cohort and Evaluation Strategy
Invasive Cohort Noninvasive Cohort
Usual Care
(n ¼ 187)
FFRCT
(n ¼ 193)
Usual Care
(n ¼ 100)
FFRCT
(n ¼ 104)
Age, yrs 63.4 60.7 57.9 59.5
Male 58% 62% 66% 58%
Diabetes 19% 16% 8% 6%
Current smoker 22% 20% 22% 22%
Hypertension 59% 58% 38% 55%
Hyperlipidemia 41% 40% 22% 27%
Atypical angina 65% 74% 91% 77%
Prior noninvasive testing 49% 52% 0% 5%
Pre-test probability of CAD 51.7% 49.4% 44.5% 45.3%
SAQ 67.0 71.6 74.1 71.8
EQ-5D 0.79 0.81 0.82 0.81
Visual analog scale 69.5 72.9 75.3 73.8
Medications
Aspirin 61% 47% 29% 43%
Statin 44% 40% 24% 28%
Clopidogrel 10% 4% 2% 5%
Values are mean or %.
CAD ¼ coronary artery disease; EQ-5D ¼ EuroQOL 5-item version; FFRCT ¼ fractional ﬂow reserve estimated
using computed tomography; SAQ ¼ Seattle Angina Questionnaire.
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2317made by the local clinicians before enrollment in the
study, and reﬂected prevailing practice patterns. The
ﬁrst cohort of patients, enrolled at the start of the
study, was evaluated by standard clinical testing in
the enrolling center. The second cohort of patients,
enrolled after completion of the enrollment of the
ﬁrst cohort, was evaluated by CTA, with determina-
tion of FFRCT when a lesion of $30% stenosis was
detected, or the patient was referred to invasive
angiography.
We followed all patients for at least 90 days to
document the primary study outcome of invasive
angiography without evidence of signiﬁcant coronary
stenosis among patients in the invasive stratum. We
enumerated the use of key medical resources from the
time of enrollment through the 90-day follow-up
visit, and counted the numbers of CTAs, noninvasive
stress tests (stress perfusion imaging, stress echocar-
diography, exercise electrocardiography, stress car-
diac magnetic resonance imaging), invasive tests
(invasive coronary angiography, invasive fractional
ﬂow reserve, optical coherence tomography, intra-
vascular ultrasound), coronary revascularization pro-
cedures (coronary artery bypass graft surgery, PCI,
number of coronary stents), cardiac medications
(aspirin, statins, antiplatelet medications), and clin-
ical events (cardiac hospitalizations, procedural
complications). We assessed quality of life (QOL) at
baseline and 90 days using the 7-item Seattle Angina
Questionnaire (SAQ) (9), the 5-item EuroQOL scale
(EQ-5D) (10), and a visual analog scale (VAS) (with
0 ¼ worst and 100 ¼ best).
We measured the cumulative medical costs over
90 days for each patient by multiplying a standard-
ized cost weight for each medical resource times the
number of resources used by the individual patient,
applying as cost weights the 2015 Medicare reim-
bursement rates (national average of technical and
professional fees) and online pharmacy costs for
drugs (Online Table 1). We did not discount costs
because of the short duration of follow-up. We
applied a range of cost weights for FFRCT, because
the Medicare reimbursement rate for this procedure
has not yet been determined. In the base case anal-
ysis, we set the cost weight for FFRCT to zero to es-
timate the cost offset attributable to use of FFRCT
(i.e., the difference in subsequent costs between
patients in the FFRCT strategy and in the conven-
tional strategy). In sensitivity analyses, we recalcu-
lated 90-day costs after application of a series of cost
weights for FFRCT that were multiples of the cost
weight for CTA.
We compared the costs of the FFRCT-guided strat-
egy with the costs of the conventional managementstrategy separately in the planned noninvasive
testing stratum and in the planned invasive testing
stratum. We compared unadjusted costs between
strategies using the nonparametric Wilcoxon rank
sum test. To control for baseline characteristics, we
created a propensity score for enrollment into the
FFRCT-guided group, and matched patients on pro-
pensity score using a greedy matching algorithm, as
described in detail in the clinical results paper (7). We
tested whether the intended form of testing (nonin-
vasive vs. invasive) signiﬁcantly modiﬁed the relative
costs of the FFRCT-guided and usual care strategies by
performing an interaction test in a log-linear model
that included stratum (noninvasive or invasive) and
strategy (FFRCT or usual care) as independent
variables.
We compared the change in QOL scores from
baseline to 90 days of follow-up using the Wilcoxon
rank sum test, and compared changes between groups
using a nonparametric test. We compared patients in
the FFRCT-guided strategy and the usual care strategy
within the pre-deﬁned strata: planned noninvasive
and planned invasive evaluation.
We performed data analyses using SAS Statistical
Software (version 9.3, Cary, North Carolina). The
institutional review boards of each enrolling center
and of Duke University Medical Center approved
the study protocol. All patients provided written,
informed consent to participate.
TABLE 2 Resource Use Over 90 Days, by Cohort and Evaluation Strategy:
Number of Times Used (Number of Patients With Any Use)
Invasive Cohort Noninvasive Cohort
Usual Care
(n ¼ 187)
FFRCT
(n ¼ 193)
Usual Care
(n ¼ 100)
FFRCT
(n ¼ 104)
Stress tests
ECG 2 (2) 8 (8) 7 (7) 4 (4)
Echo 0 (0) 1 (1) 29 (29) 1 (1)
Nuclear 2 (2) 0 (0) 15 (15) 4 (4)
CT angiograms 1 (1) 193 (193) 60 (60) 104 (104)
FFRCT 0 (0) 117 (117) 0 (0) 60 (60)
Invasive tests
Diagnostic ICA 153 (153) 37 (36) 9 (9) 10 (10)
ICA with PCI 40 (38) 51 (45) 4 (3) 9 (9)
FFRINV 11 (11) 27 (26) 0 (0) 5 (5)
IVUS 7 (7) 4 (4) 3 (3) 2 (2)
Coronary revascularization
PCI 44 (42) 51 (45) 4 (3) 9 (9)
Stents (mean) 1.82 1.80 1.25 1.22
CABG 17 (17) 10 (10) 2 (2) 1 (1)
Hospital days 445 (109) 259 (54) 28 (8) 46 (16)
Clinic visit 45 (35) 37 (36) 26 (21) 18 (16)
ED visits 8 (8) 2 (2) 1 (1) 1 (1)
Medications at 90 days
Aspirin 133 117 39 47
Statin 114 107 39 47
Clopidogrel 38 46 3 12
Prasugrel 3 3 0 0
Ticagrelor 1 0 1 0
Values are the total number of resources used (number of patients with any resource used).
CABG ¼ coronary artery bypass graft surgery; CT ¼ computed tomography; ECG ¼ electrocardiogram;
ED ¼ emergency department; FFRCT ¼ fractional ﬂow reserve estimated by coronary computed angiography;
FFRinv ¼ fractional ﬂow reserve determined by invasive coronary angiography; ICA ¼ invasive coronary angi-
ography; IVUS ¼ intravascular ultrasound; PCI ¼ percutaneous coronary intervention.
TABLE 3
Strategy
Cost
Stress tes
Coronary
Invasive te
Revascula
Medicatio
Follow-up
Other
Total
Values are m
CTA ¼ c
computed t
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2318RESULTS
The PLATFORM study enrolled 584 symptomatic pa-
tients with suspected CAD: 204 in the planned
noninvasive testing stratum and 380 in the plannedMean Medical Costs Over 90 Days, by Cohort and Evaluation
(U.S. Dollars)
Category
Invasive Cohort Noninvasive Cohort
Usual Care
(n ¼ 187)
FFRCT
(n ¼ 193)
Usual Care
(n ¼ 100)
FFRCT
(n ¼ 104)
ts 22 14 203 39
CTA 2 301 180 301
sts 2,335 570 258 280
rization 5,983 5,276 1,144 1,506
ns 60 54 23 27
hospitalization 2,301 1,107 299 506
31 22 29 20
10,734 7,343 2,137 2,679
ean U.S. dollars ($).
omputed tomography angiography; FFRct ¼ fractional ﬂow reserve estimated by
omography coronary angiography.invasive testing stratum (7). Within the planned
noninvasive testing stratum, 100 patients were eval-
uated with the usual care strategy, and 104 patients
were evaluated with the FFRCT strategy. In the plan-
ned invasive testing stratum, 187 patients were
evaluated with the usual care strategy, and 193 pa-
tients were evaluated with the FFRCT strategy.
The mean age of the study participants was 61
years, 40% were women, 74% had atypical angina,
and the mean pre-test probability of CAD was 49%
(Table 1). Clinical characteristics of patients in the
FFRCT strategy groups were generally similar to those
of patients in the usual care strategy groups (Table 1).
In the planned invasive testing stratum, CTA was,
by design, performed in 100% of the FFRCT-guided
strategy group, with FFRCT performed in 61%
(Table 2). Invasive coronary angiography was per-
formed, by design, in 100% of the patients in the
usual care strategy, compared with 39% of patients in
the FFRCT-guided strategy. Coronary revasculariza-
tion was performed in a similar proportion of patients
in each strategy (28% vs. 32%), with slightly fewer
coronary artery bypass graft procedures in the FFRCT-
guided group (5% vs. 9%). The 90-day per-patient
cost of medical care was signiﬁcantly lower in the
FFRCT-guided strategy than in the usual care strategy
($7,343 vs. $10,734; p < 0.0001; 95% conﬁdence limits
on the $3,391 difference, $1,186 to $5,595), driven
primarily by the lower costs of invasive procedures
(Table 3). The “downstream costs,” excluding the
costs of the initial tests, were $7,048 for the FFRCT
group, compared with $8,422 in the usual care group
(p < 0.0001). More patients in the FFRCT-guided
group had low costs (median ¼ $379) than in the usual
care group (median ¼ $6,414) (Figure 1). The pattern
of 90-day costs was similar whether patients had
prior noninvasive testing ($7,790 vs. $10,615), or
did not have prior noninvasive testing ($6,853 vs.
$10,849).
In the planned noninvasive testing stratum, pa-
tients in the usual care group had more stress tests
and fewer CTAs than patients in the FFRCT group, as
expected by the study design (Table 2). FFRCT was
performed in 58% of the CTAs in the FFRCT-guided
strategy and, by design, in none of the CTAs in the
usual care strategy. Invasive coronary angiography
was performed slightly more often in the FFRCT group
than in the usual care group (18% vs. 12%), as was
coronary revascularization (10% vs. 5%). The 90-day
per-patient cost of care was not signiﬁcantly
different between the FFRCT group and the usual care
group ($2,679 vs. $2,137; p ¼ 0.26; 95% conﬁdence
limits for the $542 difference, $1,153 to þ$2,237). The
“downstream costs,” excluding the costs of the initial
FIGURE 1 Ninety-Day Costs by Stratum and Evaluation Strategy
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5,000
0
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Usual
Care
FFRCT Usual
Care
FFRCT
3,000
2,500
2,000
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500
0
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p<0.0001 p=.0.26
The vertical axis indicates cumulative 90-day medical costs. The top line of each box indicates the 75th percentile, the line within each
box indicates the 50th percentile (median), and the bottom line of each box indicates the 25th percentile. Mean costs are indicated by the
point, and the error bars indicate  1 standard error of the mean. The inset shows the expanded vertical scale for the noninvasive stratum.
The p values compare the usual care and FFRCT evaluation strategies. FFRCT ¼ fractional ﬂow reserve estimated using computed
tomography.
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2319tests, were $2,412 in the FFRCT group, compared with
$1,819 in the usual care group (p ¼ 0.51). Most pa-
tients had relatively low costs in the noninvasive
stratum (Figure 1), with median costs of $349 in the
FFRCT group and $407 in the usual care group, as the
minority of patients who had costly invasive pro-
cedures drove the mean costs higher in both groups.
The effect of the FFRCT strategy, compared with
usual care, on 90-day costs differed signiﬁcantly be-
tween the noninvasive cohort and invasive cohort
(interaction p < 0.0001).
Propensity score matching did not change these
study ﬁndings materially. In the invasive testing
cohort, the cost of the FFRCT strategy was 32% lower
in the entire population (Table 3) and was 31% lower
in the 148 propensity score–matched pairs of patients
($7,473 vs. $10,833; p < 0.0001). In the planned
noninvasive testing cohort, the cost of the FFRCT
strategy was 25% higher in the entire population
(Table 3), and was 41% higher in the 80 propensity-
matched pairs of patients ($2,984 vs. $2,119; p ¼ 0.27).
In a sensitivity analysis, we assigned a series of
cost weights to FFRCT that were multiples of the cost
weight for CTA. Even when the cost weight for FFRCTwas set to 7 times the cost weight of CTA, the FFRCT-
guided strategy still had 20% lower costs than the
usual care strategy in the planned invasive testing
stratum ($8,619 vs. $ 10,734; p < 0.0001); the costs
equalized when the cost weight for FFRCT was set to
20 times the cost weight for CTA. In the planned
noninvasive testing stratum, however, a cost weight
for FFRCT one-half that of CTA led to higher mean per
patient costs over 90 days in the FFRCT group
compared with the usual care group ($2,766 vs.
$2,137; p ¼ 0.02).
QUALITY OF LIFE. Functional status and QOL
improved from baseline to 90 days of follow-up in
the overall study population, with mean improve-
ments of 16 U on the SAQ (p < 0.0001), 0.06 U
on the EQ-5D (p < 0.0001), and 4.2 U on the VAS
(p < 0.0001). In the planned noninvasive testing
stratum, the improvements in QOL scores were
greater in the patients in the FFRCT strategy group
than in patients in the usual care group: 19.45 versus
11.43 for the SAQ (p ¼ 0.003), 0.08 versus 0.03
for the EQ-5D (p ¼ 0.002), and 4.05 versus 2.26 for
the VAS (p ¼ 0.82). The mean improvements in the
SAQ subscales were generally consistent with the
FIGURE 2 Change
Evaluation Strategie
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2320improvement in the overall SAQ: 10.06 for the FFRCT
group versus 2.60 for the usual care group on the
Physical Limitation Subscale; 18.96 versus 11.69 for
the Angina Frequency Subscale, and 28.16 versus
18.32 for the Quality of Life Subscale. The FFRCT
group had greater improvements on the standard
categories for overall SAQ scale (poor to fair ¼ 0 to
<50, good ¼ 50 to <75, excellent ¼ 75 to 100): 45%
(43 of 96 patients with both baseline and 90-day
scores) improved by 1 or 2 categories on the SAQ
score versus 33% (29 of 89 patients) in the usual care
group. In the planned invasive testing stratum, thein QOL Scores From Baseline to 90 Days, by Stratum and
s
Usual
Care
FFRCT Usual
Care
FFRCT
INVASIVE NON–INVASIVE
p=0.54 p=0.003
p=0.10 p=0.002
p=0.48 p=0.82
1. DEQ-5D ¼ Change in EuroQol; DSAQ ¼ change in Seattle Angina
¼ Change in visual analog scale; FFRCT ¼ fractional ﬂow reserve
puted tomography; QOL ¼ quality of life.improvements in the QOL scores were similar in
the FFRCT and usual care strategy groups (Figure 2).
These ﬁndings were not materially changed in the
propensity score–matched population.
DISCUSSION
In this multicenter, prospective study of stable,
symptomatic patients with suspected CAD, an eval-
uation strategy based on use of FFRCT was associated
with lower use of medical resources and signiﬁcantly
lower costs compared with a strategy of invasive
coronary angiography (Central Illustration). The
FFRCT-guided testing strategy was associated with
less than one-half the rate of invasive coronary
angiography, similar rates of overall coronary revas-
cularization, and similar degrees of improvement in
QOL than the invasive testing strategy (Central
Illustration). These ﬁndings suggest that the combi-
nation of anatomic and functional data provided by
the FFRCT-guided testing strategy may lead to more
selective use of invasive procedures than relying
solely on the anatomic data provided by invasive
coronary angiography.
Among patients who had planned noninvasive
testing, the FFRCT-guided strategy was associated
with slightly more use of invasive cardiac procedures,
and a trend towards higher medical costs, but the
FFRCT-guided strategy was also associated with a
signiﬁcantly greater improvement in QOL. In the
noninvasive setting, the combination of anatomic and
functional data provided by CTA and FFRCT may
identify patients who would beneﬁt from coronary
revascularization.
The overall effect on costs of an FFRCT-based
evaluation strategy depends mostly on the relative
cost of performing CTA and FFRCT. The Medicare
reimbursement rate for FFRCT has not yet been
established, so we tested a range of cost weights for
FFRCT in a sensitivity analysis. Even when the cost
weight for FFRCT was set to 7 times the cost weight of
CTA, the FFRCT-guided strategy still had 20% lower
cost than the invasive testing strategy (p < 0.0001),
and the cost of these strategies was equalized only
when the cost weight for FFRCT was set to 20 times
the cost weight for CTA. These ﬁndings suggest that
use of FFRCT-guided evaluation could be cost saving
compared with invasive testing under most likely
levels of reimbursement for FFRCT.
In light of the importance many cardiologists
place upon images of coronary anatomy, the impact
of functional data from FFRCT on clinical decision
making appears to be context speciﬁc: functional
data from FFRCT added to anatomic data might
CENTRAL ILLUSTRATION Measuring FFRCT: QOL and Cost Outcomes in the PLATFORM Study
Planned Noninvasive
P <0.0001                                                                            P = 0.26
$10,734
$7,343
$2,137 $2,679
Cost
P = 0.54                                                                               P = 0.003
Δ SAQ   
+11.4
+15.5 +16.9
+19.5
Usual Care                        FFRct                                            Usual Care                       FFRct
(N = 187)                      (N = 193)                                          (N = 100)                     (N = 104)
Enrolled and Consented Patients (N = 584)
 Hlatky, M.A. et al. J Am Coll Cardiol. 2015; 66(21):2315–23.
DSAQ ¼ Change in Seattle Angina Questionnaire; FFRCT ¼ fractional ﬂow reserve estimated using computed tomography; QOL ¼ quality of life.
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2321reduce invasive procedures compared with anatomic
data alone, but anatomic data from the CTA added to
functional data might increase invasive procedures
compared with functional data alone. This interpre-
tation is consistent with prior evidence from ran-
domized and observational studies of the effect on
resource use of CTA compared with noninvasive
stress testing. In the PROMISE trial (Prospective
Multicenter Imaging Study for Evaluation of Chest
Pain) (2), patients randomly assigned to initial
anatomic testing with CTA were more likely to un-
dergo invasive coronary angiography (12.2% vs. 8.1%)
and coronary revascularization (6.2% vs. 3.2%;
p < 0.001) than patients randomly assigned to
noninvasive stress testing. SCOT-HEART (Scottish
Computed Tomography of the Heart Trial) also re-
ported an increase in invasive procedures amongpatients randomly assigned to CTA compared with
patients assigned to standard care (11). An ob-
servational study of Medicare beneﬁciaries matched
on propensity score found that patients who received
CTA were more likely to undergo subsequent in-
vasive coronary angiography than patients who
received stress testing (3). Similar ﬁndings were re-
ported by the SPARC Registry, which compared CTA
with stress myocardial perfusion imaging (4). How-
ever, none of these previous studies comparing CTA
with other noninvasive tests used FFRCT to evaluate
the functional signiﬁcance of the visualized lesions.
QOL improved in all patient groups in the PLAT-
FORM study (Figure 2), potentially reﬂecting the
initiation of treatments based on the test results in
these patients with new onset of symptoms sugges-
tive of CAD. Patients who were most symptomatic
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Fractional ﬂow reserve assesses the functional
importance of coronary lesions visualized by angiog-
raphy, and can be estimated noninvasively on the
basis of data from coronary CTA.
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: Clinical guidelines recommend
assessment of the functional signiﬁcance of coronary
lesions before coronary revascularization.
TRANSLATIONAL OUTLOOK: The PLATFORM
study suggests that use of FFRCT may reduce overall
costs and improve patient quality of life. Larger,
randomized studies are warranted to compare the
clinical effectiveness of management strategies
based on use of FFRCT with management strategies
based on using other methods of anatomic or func-
tional evaluation.
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2322at baseline (i.e., had lower SAQ scores) generally
had more QOL improvement, as did patients who
underwent coronary revascularization. The degree of
improvement in QOL differed somewhat depending
upon the evaluation strategy used and the initially
planned method of evaluation (noninvasive or inva-
sive). In the planned invasive testing stratum, the
improvements in QOL were similar in the usual care
and FFRCT-guided groups, perhaps because of the
similar, and overall high, rates of coronary revascu-
larization. By contrast, in the planned noninvasive
testing stratum, QOL improved to a greater degree
among patients in the FFRCT-guided strategy. The
reasons for this greater degree of improvement are
uncertain and difﬁcult to assess due to the non-
randomized and unblinded study design, but may be
due to more frequent use of coronary revasculariza-
tion for functionally signiﬁcant coronary lesions,
which has been previously shown to reduce angina
and improve QOL (5).
This study assessed the impact of using an FFRCT-
guided strategy on economic and quality-of-life out-
comes, but was too small to evaluate its effect on
major cardiac events. As reported previously (7), the
rate of the composite outcome (death, myocardial
infarction, and unstable symptoms requiring urgent
revascularization) was low in both evaluation strate-
gies and did not differ signiﬁcantly. A substantially
larger study would be required to detect clinically
meaningful changes in major cardiac events as a
result of using an FFRCT-guided evaluation strategy.
The 10,003 patient PROMISE randomized trial of CTA
and stress testing, with 315 primary outcome events
over 25 months of follow-up (1.5% per year), found no
signiﬁcant difference in the rate of major cardiac
events, but this ﬁnding had relatively wide conﬁ-
dence intervals (hazard ratio 1.04, conﬁdence limits
0.83 to 1.29). Very large outcome studies would be
needed to assess the effect of using FFRCT on hard
cardiac outcomes in low risk patients such as those
enrolled in the PLATFORM study.
STUDY LIMITATIONS. The major limitation of this
study was that it used a consecutive observational
design, and did not randomize patients to evaluation
with FFRCT. The balance of patient characteristics
and the lack of meaningful change in the study
results after propensity score matching suggest that
the ﬁndings are not due to baseline differences be-
tween patient groups. This study was conducted in 11
European centers, and the practice patterns at these
centers may not be representative of other centers,
and practice patterns may differ between Europe and
the United States. This study used Medicare costweights because they are a widely applicable metric
of economic impact. Although alternative sets of price
weights might alter these conclusions somewhat, the
cost of noninvasive testing is lower than the cost of
invasive coronary angiography and coronary revas-
cularization in essentially all health care settings, so
the overall conclusions are unlikely to be sensitive
to variations in the cost weights. Finally, this study
examined a strategy of using FFRCT to guide man-
agement among patients eligible to undergo coronary
CTA testing, but FFRCT may not be technically
feasible in all patients. In the PLATFORM study, 88%
of CTAs performed were of sufﬁcient quality to assess
FFRCT.
CONCLUSIONS
A strategy of using CT angiography with FFRCT to
evaluate patients with suspected CAD was associated
with lower costs than a strategy of invasive coronary
angiography, and was associated with improved QOL
compared with a strategy of evaluation with other
noninvasive tests.
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